Xanax (alprazolam) is not approved to treat depression, but research suggests it can reduce depressive symptoms in the short term. The catch: it carries serious risks that make it a poor choice as a standalone depression treatment, and stopping it can make mood problems worse than they were before.
What Xanax Is Actually Approved For
The FDA has approved Xanax for two conditions in adults: acute treatment of generalized anxiety disorder and treatment of panic disorder (with or without agoraphobia). Depression is not on that list. In fact, the prescribing label specifically warns clinicians to exercise caution in patients showing signs of depression, and to limit prescription sizes for those patients due to overdose risk.
That said, “not FDA-approved for depression” doesn’t mean it has zero effect on depressive symptoms. It means the drug was never put through the full approval process for that use, and the balance of benefits versus risks hasn’t been deemed favorable enough to earn that indication.
What the Research Shows
A Cochrane-style review published in PubMed Central pooled data from multiple trials comparing alprazolam to placebo in people with major depression. The results were surprisingly positive: for every three people treated with alprazolam, one additional person experienced a meaningful clinical response (defined as a 50% improvement in symptoms) compared to placebo. The review concluded that alprazolam may be moderately more effective than placebo and roughly as effective as conventional antidepressants for major depression.
That sounds like good news, but context matters. These trials measured short-term symptom reduction. Xanax works fast, often producing noticeable effects within one to two weeks. Standard antidepressants like SSRIs typically take three to six weeks to reach full effect. So in head-to-head comparisons over a few weeks, Xanax can look competitive simply because it acts sooner. The real question is what happens beyond that window.
Why It Works on Mood at All
Xanax enhances the activity of GABA, the brain’s main calming chemical. It binds to GABA receptors and makes them more responsive, which slows down nervous system activity. This produces the familiar effects: reduced anxiety, muscle relaxation, sedation. Because anxiety and depression overlap so heavily, quieting the anxious component of someone’s mood can make the depression feel lighter too.
But Xanax doesn’t address the neurochemical pathways most closely linked to depression, like serotonin and norepinephrine signaling. It’s more like turning down the volume on distress than fixing the underlying signal. For people whose depression is heavily driven by anxiety, that volume reduction can feel like real relief. For people with depression that isn’t anxiety-driven, the benefit is less clear.
The Withdrawal Problem
This is where the picture gets much darker. Xanax has a short half-life, meaning it leaves your system quickly. That rapid drop creates a cycle of relief and rebound that makes it particularly hard to stop. In one study of 126 people with panic disorder, 27% experienced rebound anxiety that was worse than what they started with after discontinuing Xanax, even with a four-week taper. Another 35% developed new physical symptoms like insomnia, rapid heart rate, and dizziness.
The mood consequences of withdrawal can be severe. In a small case series of combat veterans, all eight patients developed worsening anxiety and sleep problems when tapering off alprazolam. Seven became irritable and hyperalert. Four experienced suicidal thoughts. These withdrawal effects occurred despite a gradual taper lasting over eight weeks on average.
Researchers have noted that alprazolam withdrawal tends to be more complicated than withdrawal from other benzodiazepines. The combination of its short duration of action, high potency, and unique effects on certain stress-related brain receptors creates a rebound that can include not just a return of the original symptoms, but symptoms that are more intense and accompanied by new problems that weren’t there before.
How It Compares to Standard Antidepressants
SSRIs and similar antidepressants work differently in almost every way that matters for long-term depression management. They take longer to kick in, typically three to six weeks, but they address core mood-regulating pathways. Their benefits tend to build over months. In panic disorder trials, SSRI panic-free rates climbed from about 55% at three months to 85% at one year. Benzodiazepines, by contrast, show little controlled evidence of sustained benefit for conditions like generalized anxiety over the long term.
Antidepressants also don’t produce the same kind of physical dependence. You can experience discontinuation symptoms when stopping an SSRI, but they’re generally milder and shorter-lived than benzodiazepine withdrawal. There’s no equivalent of the severe rebound anxiety that characterizes Xanax discontinuation.
The one area where Xanax has a clear advantage is speed. Some clinicians use it as a short-term “bridge” during the first few weeks of antidepressant treatment, covering the gap before the antidepressant reaches full effect. In this role, it’s used on an as-needed basis for acute anxiety or panic episodes, not as the primary treatment for depression itself.
When Anxiety and Depression Overlap
Many people searching this question likely have both anxiety and depression, which is extremely common. About half of people diagnosed with one also meet criteria for the other. In these cases, Xanax might seem appealing because it tackles the anxiety piece quickly.
Current treatment approaches for this overlap generally prioritize antidepressants that treat both conditions simultaneously, particularly SSRIs and SNRIs, which have strong evidence for both anxiety and depression. Benzodiazepines like Xanax may be added temporarily for acute panic episodes while the antidepressant builds up in your system. The key word is temporarily. The goal is to taper off the benzodiazepine once the antidepressant is working.
Risks Specific to Depression
Xanax is classified as a central nervous system depressant, which is a pharmacological term (it slows brain activity), not a statement about mood. But for someone already experiencing depression, that slowing effect can be a problem. The Mayo Clinic lists a history of depression as a condition that may be worsened by alprazolam use.
There’s also the sedation factor. Depression often already involves fatigue, low motivation, and difficulty concentrating. A drug that adds drowsiness and cognitive slowing on top of those symptoms can make the functional impairment of depression worse, even if it takes the edge off emotional distress. Some people describe feeling calmer but less capable, which isn’t the same as feeling better.
The dependence risk adds another layer. Tolerance can develop, meaning you need higher doses for the same effect. For someone using Xanax to manage depressive symptoms, this creates a situation where the drug works less over time but stopping it makes everything worse. That’s a trap that’s difficult to escape without professional support and a careful, often slow, tapering plan.